News & Events

With the outlicensing of our HSV-2 vaccine program to Eurocine Vaccines (Sweden) Redbiotec has achieved one of its biggest goals for the business year 2022. Redbiotec keeps its focus on the development of relevant proteins for biopharma and food industry.

https://www.eurocine-vaccines.com/eurocine-vaccines-expands-its-portfolio-with-a-therapeutic-hsv-2-vaccine-candidate/

Redbiotec has successfully expressed the kappa casein, an essential protein for the production of animal-free milk, in an innovative expression platform. Redbiotec has confirmed that its proprietary production process leads to post-translational modifications by glycosylation and phosphorylation, which are required for the casein functional properties. Furthermore, manufacturing processes are currently under development for small/mid and large scales for kappa and other caseins.

Redbiotec has expanded its platform by adding further microorganisms. In order to express proteins and small molecules at high yield, among other for the manufacturing of products in the food industry, Redbiotec has implemented yeast and bifidobacteria.

Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will leverage Redbiotec’s proprietary bacteria platform BRISPR^® for the targeted delivery of gene therapy cargos from the partner.

“Redbiotec’s bacteria hold great potential in overcoming the delivery hurdles faced by conventional vehicles, such as adeno-associated viruses (AAVs) and nanoparticles. It is our goal to empower promising gene therapies for unmet medical needs through safe and targeted delivery,” said Christian Schaub, CEO of Redbiotec. “We are very pleased with our first pharma partnership on the BRISPR^® platform. Together, we will push the boundaries and create a new class of genetic medicines.”